Clinical Trials Browser

Has results × olaparib × Thoracic × Clear all

Non-small Cell Lung Cancer NSCLC

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Completed

45 enrolled 30 charts

GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 11 charts

EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03531840 2021-04-09

Olaparib in People With Malignant Mesothelioma

Phase 2 Completed

23 enrolled 16 charts

Other solid neoplasmThoracic

Mesothelioma

Clinical Trials

ORION

MEDIOLA

HUDSON

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

GOAL

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Olaparib in People With Malignant Mesothelioma